<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Ono Pharmaceutical Co., Ltd. — News on 6ix</title>
<link>https://6ix.com/company/ono-pharmaceutical-co-ltd</link>
<description>Latest news and press releases for Ono Pharmaceutical Co., Ltd. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 03 Mar 2026 13:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/ono-pharmaceutical-co-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d62165beedb30cb6fc2b8a.webp</url>
<title>Ono Pharmaceutical Co., Ltd.</title>
<link>https://6ix.com/company/ono-pharmaceutical-co-ltd</link>
</image>
<item>
<title>Sinopia Biosciences Announces Target Discovery Collaboration with Ono Pharmaceutical for Rare Metabolic Disorders</title>
<link>https://6ix.com/company/ono-pharmaceutical-co-ltd/news/sinopia-biosciences-announces-target-discovery-collaboration-with-ono-pharmaceutical-for-rare-metabolic-disorders</link>
<guid isPermaLink="true">https://6ix.com/company/ono-pharmaceutical-co-ltd/news/sinopia-biosciences-announces-target-discovery-collaboration-with-ono-pharmaceutical-for-rare-metabolic-disorders</guid>
<pubDate>Tue, 03 Mar 2026 13:00:00 GMT</pubDate>
<description>SAN DIEGO, March 03, 2026--Sinopia Biosciences, Inc., a biotechnology company advancing novel therapeutics discovered using its proprietary LEADS® (LEarn And DiScover) drug discovery platform, today announced a target discovery collaboration with Ono Pharmaceutical Co., Ltd. focused on an undisclosed group of rare metabolic disorders with significant unmet medical need.</description>
</item>
<item>
<title>Congruence and Ono Pharma Expand Multi-Target Research Partnership with the Addition of Two New Programs</title>
<link>https://6ix.com/company/ono-pharmaceutical-co-ltd/news/congruence-and-ono-pharma-expand-multi-target-research-partnership-with-the-addition-of-two-new-programs</link>
<guid isPermaLink="true">https://6ix.com/company/ono-pharmaceutical-co-ltd/news/congruence-and-ono-pharma-expand-multi-target-research-partnership-with-the-addition-of-two-new-programs</guid>
<pubDate>Mon, 02 Mar 2026 22:00:00 GMT</pubDate>
<description>Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono") and Congruence Therapeutics today announced that they have expanded their existing multi-target research partnership through the execution of a new research collaboration for two additional programs.</description>
</item>
<item>
<title>Ono Shares Replay Information for 44th Annual J.P. Morgan Healthcare Conference Presentation</title>
<link>https://6ix.com/company/ono-pharmaceutical-co-ltd/news/ono-shares-replay-information-for-44th-annual-jp-morgan-healthcare-conference-presentation</link>
<guid isPermaLink="true">https://6ix.com/company/ono-pharmaceutical-co-ltd/news/ono-shares-replay-information-for-44th-annual-jp-morgan-healthcare-conference-presentation</guid>
<pubDate>Thu, 15 Jan 2026 14:45:00 GMT</pubDate>
<description>OSAKA, Japan, January 15, 2026--Ono Pharmaceutical Co., Ltd. (TSE:4528), today announced that Toichi Takino, President and COO, presented at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 11:15 a.m. PST / 2:15 p.m. EST.</description>
</item>
<item>
<title>Ono to Participate in the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/ono-pharmaceutical-co-ltd/news/ono-to-participate-in-the-44th-annual-jp-morgan-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/ono-pharmaceutical-co-ltd/news/ono-to-participate-in-the-44th-annual-jp-morgan-healthcare-conference</guid>
<pubDate>Mon, 12 Jan 2026 12:00:00 GMT</pubDate>
<description>OSAKA, Japan, January 12, 2026--Ono Pharmaceutical Co., Ltd. (TSE:4528) today announced that Toichi Takino, President and COO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 11:15 a.m. PST / 2:15 p.m. EST.</description>
</item>
<item>
<title>Scenic Biotech Enters License and Research Agreement with Ono Pharmaceutical</title>
<link>https://6ix.com/company/ono-pharmaceutical-co-ltd/news/scenic-biotech-enters-license-and-research-agreement-with-ono-pharmaceutical</link>
<guid isPermaLink="true">https://6ix.com/company/ono-pharmaceutical-co-ltd/news/scenic-biotech-enters-license-and-research-agreement-with-ono-pharmaceutical</guid>
<pubDate>Wed, 07 Jan 2026 10:00:00 GMT</pubDate>
<description>Amsterdam, the Netherlands, January 7, 2026 – Scenic Biotech, a pioneer in the field of modifier therapies for severe diseases, today announced a license and research agreement with Ono Pharmaceutical Co., Ltd. to utilize Scenic’s Cell-Seq platform for the discovery of novel therapeutic targets. “This collaboration with Ono Pharmaceutical represents another strong validation of our platform’s ability to uncover new disease biology and identify novel targets for rare and common indications,” said</description>
</item>
<item>
<title>Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting</title>
<link>https://6ix.com/company/ono-pharmaceutical-co-ltd/news/deciphera-announces-oral-presentation-of-positive-topline-results-from-phase-2a-study-of-sapablursen-in-polycythemia-vera-at-the-67th-american-society-of-hematology-ash-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/ono-pharmaceutical-co-ltd/news/deciphera-announces-oral-presentation-of-positive-topline-results-from-phase-2a-study-of-sapablursen-in-polycythemia-vera-at-the-67th-american-society-of-hematology-ash-annual-meeting</guid>
<pubDate>Sat, 06 Dec 2025 14:30:00 GMT</pubDate>
<description>OSAKA, Japan & WALTHAM, Mass., December 06, 2025--Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono"), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL.</description>
</item>
<item>
<title>PRISM BioLab Achieved Initial Milestone and Receives the Milestone Payment in Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd.</title>
<link>https://6ix.com/company/ono-pharmaceutical-co-ltd/news/prism-biolab-achieved-initial-milestone-and-receives-the-milestone-payment-in-drug-discovery-collaboration-with-ono-pharmaceutical-co-ltd-1</link>
<guid isPermaLink="true">https://6ix.com/company/ono-pharmaceutical-co-ltd/news/prism-biolab-achieved-initial-milestone-and-receives-the-milestone-payment-in-drug-discovery-collaboration-with-ono-pharmaceutical-co-ltd-1</guid>
<pubDate>Fri, 14 Nov 2025 08:00:00 GMT</pubDate>
<description>PRISM BioLab, Co. Ltd. ("PRISM") announces that today, PRISM and Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka; President and COO: Toichi Takino; hereinafter "Ono") have achieved the initial milestone in the drug discovery collaboration and PRISM has confirmed receipt of the milestone payment.</description>
</item>
<item>
<title>Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment</title>
<link>https://6ix.com/company/ono-pharmaceutical-co-ltd/news/harness-therapeutics-announces-launch-of-misbar-duo-platform-and-research-collaboration-with-ono-venture-investment</link>
<guid isPermaLink="true">https://6ix.com/company/ono-pharmaceutical-co-ltd/news/harness-therapeutics-announces-launch-of-misbar-duo-platform-and-research-collaboration-with-ono-venture-investment</guid>
<pubDate>Mon, 06 Oct 2025 06:00:00 GMT</pubDate>
<description>Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment Proprietary MISBA Duo technology is the first platform to enable simultaneous, controlled upregulation and downregulation of two targets R&D programme with Ono Venture Investment builds on insights from first generation platform, and targets an undisclosed rare triplet repeat disorder Cambridge, UK, 06 October 2025: Harness Therapeutics (‘Harness’), a biotechnology company unlockin</description>
</item>
<item>
<title>Deciphera Announces Positive CHMP Opinion for ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)</title>
<link>https://6ix.com/company/ono-pharmaceutical-co-ltd/news/deciphera-announces-positive-chmp-opinion-for-romvimzatm-vimseltinib-for-the-treatment-of-tenosynovial-giant-cell-tumor-tgct</link>
<guid isPermaLink="true">https://6ix.com/company/ono-pharmaceutical-co-ltd/news/deciphera-announces-positive-chmp-opinion-for-romvimzatm-vimseltinib-for-the-treatment-of-tenosynovial-giant-cell-tumor-tgct</guid>
<pubDate>Mon, 28 Jul 2025 11:00:00 GMT</pubDate>
<description>OSAKA, Japan & WALTHAM, Mass., July 28, 2025--Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines, and Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono"), today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of vimseltinib for the treatment of adu</description>
</item>
<item>
<title>Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea</title>
<link>https://6ix.com/company/ono-pharmaceutical-co-ltd/news/vertex-and-ono-pharmaceutical-announce-strategic-agreement-to-develop-and-commercialize-povetacicept-in-japan-and-south-korea-1</link>
<guid isPermaLink="true">https://6ix.com/company/ono-pharmaceutical-co-ltd/news/vertex-and-ono-pharmaceutical-announce-strategic-agreement-to-develop-and-commercialize-povetacicept-in-japan-and-south-korea-1</guid>
<pubDate>Mon, 23 Jun 2025 08:00:00 GMT</pubDate>
<description>BOSTON & OSAKA, Japan, June 23, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept in Japan and South Korea. Povetacicept is a recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines with best-in-class potential bein</description>
</item>
</channel>
</rss>